Global Her2 Antibodies Market: Overview
Human epidermal growth factor receptor 2 (Her2) refers to an oncogene whose over-expression or amplification is commonly associated with the development of an aggressive type of breast cancer. Patients having the over-expression of Her2 receptors are diagnosed with the help of tests such as Fluorescent In-Situ Hybridization (FISH) and Immunohistochemistry (IHC).
The American Cancer Society states that around 15-30% of breast cancer cases over-express the Her2 gene. Her2 antibodies are reported to mediate the regression of tumor by interrupting oncogenic signals and/or inducing Fc receptor-mediated cytotoxicity. The field of Her2 antibodies has witnessed a significant rise in attention over the past few years owing to the effectiveness of Her2 antibody-based drugs and rising prevalence of breast cancer.
Obtain Report Details: http://www.transparencymarketresearch.com/her2-antibodies-market.html
Global Her2 Antibodies Market: Drivers and Opportunities
The global market for Her2 antibodies will be chiefly driven by the rising prevalence of breast cancer and an encouraging scenario of funding and regulatory support from cancer associations across the globe. The American Cancer Society estimates that about 252,710 new cases of invasive breast cancer will be diagnosed in the U.S. in 2017. About 63,410 new cases of non-invasive and earliest forms of breast cancer are expected to be diagnosed in the country this year. Number of deaths resulting from breast cancer will reach 40,610, estimates the organization.
The numbers are equally alarming across other regional markets and the situation calls for effective interventions for the treatment of the disease. Efforts directed towards this cause in the form of research and development will have a significant impact on the overall development of the global Her2 antibodies market in the next few years.
Global Her2 Antibodies Market: Geographical Overview
From a geographical standpoint, the report covers the market for Her2 antibodies for regional markets such as North America, Europe, Asia Pacific, and Middle East and Africa. Of these, the North America market presently domiantes the global Her2 antibodies market owing to the high prevalence of breast cancer. The high disposable incomes and favorable reimbursement policies make Her2 antibody treatment affordable for patients in the region, which is also a key factor to have driven the market for Her2 antibodies over the past few years.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7301
Over the report’s forecast period as well, North America will remain a lucrative regional market for Her2 antibodies, with factors such as the rapid pace of introduction of novel drug candidates and biosimilars boosting growth. Europe will also remain a key contributor of revenue to the global Her2 antibodies market, chiefly owing to favorable medical insurance policies and high disposable incomes of the population. The market for Her2 antibodies in regions such as Asia Pacific will be driven chiefly due to regulatory support and the increased adoption of chemotherapy for the treatment of breast cancer.
Global Her2 Antibodies Market: Competitive Dynamics
The key Her2 antibodies available in the global market for the treatment of breast cancer include lapatinib (Tykerb), tratuzumab (Herceptin), Pertuzumab (Perjeta), Everolimus (Afinitor), and Ado-trastuzumab emtansine (TDM-1, Kadcyla). Of these, tratuzumab (Herceptin) is presently the most widely prescribed Her2 antibody drug for breast cancer. The expiry of this drug’s patent in the European market in July 2014 led to the introduction of biosimilars. Roche will continue to own the patent for the drug in the U.S. until 2019. The company plans to launch new drugs in the Her2 antibody category – Pertuzumab (Perjeta) and Ado-trastuzumab emtansine (TDM-1, Kadcyla).
The high demand for effective methods of treating breast cancer has opened vast growth opportunities for companies operating in the field of Her2 antibodies. The ever-expanding window of opportunity in the field has compelled many pharmaceutical companies to invest their funds and research efforts towards the development of effective drugs based on Her2 antibodies. Some of the leading players operating in the field are Epirus Biopharmaceuticals, Hospira, Inc., Genentech Inc., Biocon Limited, Avesthagen Pharma, Mylan Pharmaceuticals, and Celltrion, Inc.